Stocktoria
PALISADE BIO, INC. PALI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2006-12-20
PALISADE BIO, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $300,000 | $0 | — |
| R&D expense | — | $16.0M | — | — | — |
| Operating income | -$18.1M | -$14.9M | -$13.1M | -$15.7M | -$41.9M |
| Interest expense | — | $12,000 | $15,000 | $13,000 | $2.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$16.8M | -$14.4M | -$12.3M | -$14.3M | -$26.6M |
| EPS (diluted) | $-0.30 | $-10.19 | $-27.01 | $-16.53 | $-169.74 |
| Operating cash flow | -$10.8M | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Free cash flow | — | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Cash & equivalents | $133.4M | $9.8M | $12.4M | $12.4M | $10.5M |
| Total assets | $134.3M | $10.9M | $14.1M | $15.8M | $12.5M |
| Total liabilities | $5.0M | $3.4M | $2.7M | $3.3M | $5.1M |
| Shareholders' equity | $129.4M | $7.5M | $11.3M | $12.5M | $7.4M |
Source: SEC EDGAR filings · CIK 0001357459 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.